The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study

NCT06962189 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer (Stage III)

Interventions

DRUG: chemoimmunothrapy

Sponsor

Zhejiang University